Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

  • National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease.
  • Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.
  • Puppies treated with CPMA had a 93% survival rate and returned home an average of 1.87 days sooner.1,2
  • Elanco's ParvoTrack, the first-ever national online parvo tracking tool, allows pet owners and veterinarians to self-report outbreaks in real time, further highlighting the need for CPMA across the country and reinforcing Elanco's commitment to increasing the availability of CPMA.
  • Texas, Arizona, Georgia, Florida, Illinois, Indiana and New York have some of the highest reported cases of canine parvovirus outbreaks according to ParvoTrack.

GREENFIELD, Ind. , April 22, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today recognizes the second annual National Parvo Awareness Day, aimed at increasing awareness of canine parvovirus, a highly contagious and often-fatal puppy disease. Since receiving conditional approval from the USDA, Canine Parvovirus Monoclonal Antibody (CPMA) has helped save thousands of puppies.3 Although parvovirus can strike anytime, late spring and summer months are the most common for outbreaks nationwide.

Experience the full interactive Multichannel News Release here: https://www.multivu.com/elanco/9306451-en-elanco-animal-health-second-annual-national-parvo-awareness-day